Brief: Phio Pharmaceuticals Announces Regulatory Clearance Of Clinical Trial For PH-762 To Treat Melanoma
11/01/2022 12:47
Jan 11 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS ANNOUNCES REGULATORY CLEARANCE OF
CLINICAL
TRIAL FOR PH-762 TO TREAT MELANOMA
* PHIO PHARMACEUTICALS - FRENCH REGULATORY AUTHORITIES GRANT
CLINICAL TRIAL AUTHORIZATION WITH DOSING OF FIRST PATIENT
ANTICIPATED IN Q1 FOR PH-762
Source text for Eikon: ID:nPnCbdrNa
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing